SUMMARY
Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of TGF-β. Because TGF-β promotes bone metastases from other solid tumors such as breast cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared to parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-β target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, PTHrP and IL-11, the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative RT-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-β, and that Smad7, and the TβRI small molecule inhibitor, SB431542, prevented such induction. Also, 1205Lu-Smad7 metastases expressed significantly lower levels of IL-11, CTGF and PTHrP. These data suggest that TGF-β promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an effective treatment for melanoma metastasis to bone.
INTRODUCTION
Transforming growth factor (TGF)-β is a prototypic multifunctional cytokine whose broad modulatory activity affects numerous biological functions. At the organism level, these include, but are not limited to, control of immune functions, embryogenesis, carcinogenesis and tissue responses to injury. At the cell level, TGF-β controls proliferation, migration, as well as extracellular matrix (ECM) synthesis and degradation (1) (2) (3) (4) (5) . The complexity of the role played by TGF-β in cancer and metastasis is underscored by the duality of this growth factor, depending on the stage of the disease (6) (7) (8) . Thus, even though the TGF-β signaling cascade functions as a tumor suppressor pathway in early carcinogenesis, mainly through the ability of TGF-β to inhibit the cell cycle, it paradoxically favors tumor progression during late-stage metastatic progression of tumors.
TGF-β signal transduction occurs via ligand-activated heterotetrameric serine/threonine kinase receptors (TβRI and TβRII) on the cell surface, which phosphorylate the cytoplasmic proteins Smad2 and Smad3. These receptor-regulated Smads (R-Smads) are ligand-specific and, upon activation, associate with Smad4, a common partner to all receptor-regulated Smads activated by the various ligands of the TGF-β family. R-Smad/Smad4 heterocomplexes then translocate into the cell nucleus to regulate target gene transcription (5, 9) . The inhibitory Smad, Smad7, interferes with Smad signaling by various means: (a), it binds activated TβRI to prevent phosphorylation of Smad2/3; (b), it recruits E3 ubiquitinligases such as Smurf1, Smurf2 and WWP1, to the activated TGF-β receptor complexes, leading to their proteasomal degradation; (c), it interacts with GADD34, the regulatory subunit of the protein phosphatase PP1, thereby recruiting it to TβRI to inactivate the latter (10) (11) (12) .
The impact of TGF-β on melanoma progression is just beginning to unravel. Malignant melanomas secrete high amounts of TGF-β, whose autocrine and paracrine effects contribute directly and indirectly to tumor progression (13) . Indeed, we previously identified that melanoma cell-derived TGF-β results in high, ligand-dependent, constitutive Smad3-driven transcriptional activity (14) . Also, we identified that overexpression of Smad7 inhibits melanoma cell MMP-2 and MMP-9 production, dramatically impairs their invasive capacity in vitro, reduces anchorage-independent growth, and delays subcutaneous tumor growth in nude mice (15) . These findings underscore the notion that intact, or exacerbated, Smad signaling occurs throughout tumor progression in melanoma cells.
In experimental models of metastasis, it has been shown that TGF-β is essential for breast cancer cells to form bone metastases (16, 17) . Furthermore, the release of TGF-β from the bone matrix upon activation of osteoclasts by soluble factors, such as parathyroid hormonerelated protein (PTHrP) derived from cancer cells, further exacerbates the latter and enhances the growth of metastases, thereby establishing what has been viewed as a vicious cycle orchestrated by TGF-β (18, 19) .
In this report, we demonstrate that Smad7 overexpression delays the establishment and growth of melanoma bone metastases in a mouse model. Also, we determine that inhibition of the Smad cascade in melanoma cells represses the expression of a panel of TGF-β-dependent genes that was previously identified as critical for the establishment of bone metastases by breast cancer cells (17) .
MATERIALS AND METHODS

Cell cultures and reagents
Melanoma cell lines WM239-A, WM1341-A, WM983-A, WM793, WM983-B, WM852, and 1205Lu, kind gifts from Dr. M. Herlyn, Wistar Institute, Philadelphia, PA, have been previously described (14, 20, 21) . They were grown in a composite medium (W489) consisting of three parts MCDB153 and one part L15 supplemented with 4% fetal calf serum (FCS) and antibiotics. Melanoma cell lines Dauv-1, 888-mel, 501-mel, SK-28, and FO-1 have been described previously (22) . They were grown in RPMI medium supplemented with 10% FCS and antibiotics. Human lung fibroblasts (WI-26) were grown in DMEM containing 10% FCS and antibiotics. Generation of Smad7 expressing clones (S7.a and S7.c) and mocktransfected cells has been described previously (15) . All cells were grown at 37°C, 5% CO 2 in a humidified atmosphere. The Smad3/4-specific reporter plasmid (CAGA) 9 
Biochemical methods
Protein extraction and Western blotting were performed as previously described (24) . AntiSmad3 and anti-β-actin were from Zymed (San Francisco, CA) and Sigma-Aldrich, respectively. The rabbit anti-phospho-Smad2/3 antibody (25) was a generous gift from E. 
Animal experiments
The animal protocols for bone metastasis experiments were approved by the Institutional Animal Care and Use Committee at the University of Virginia in Charlottesville and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Athymic female nude mice 4 weeks of age were housed in laminar flow isolated hoods. Water supplemented with vitamin K and autoclaved mouse chow were provided ad libitum. Radiographs were taken under mouse anesthesia mixture (30% ketamine and 20% xylazine in 0.9% NaCl). Tumor inoculation into the left cardiac ventricle was performed on anesthetized mice positioned ventral side up, as described previously (26) . Briefly, the left cardiac ventricle was punctured percutaneously using a 26-gauge needle attached to a 1-ml syringe containing suspended tumor cells. Visualization of bright red blood entering the hub of the needle in a pulsatile fashion indicated a correct position in the left cardiac ventricle.
Tumor cells (10 5 in 0.1 ml of PBS) were inoculated slowly over 1 min. Mice were followed by radiography for the development of bone lesions throughout the experiments. Mice were x-rayed in a prone and lateral position using a Digital Faxitron MX-20 with digital camera (Faxitron x-ray, Wheeling, IL), as described previously (26) . Radiographs where taken at 1X magnification and when a lesion was suspected, additional images with higher magnification (4X) were taken. Images were saved and lesion areas were measured and analyzed using
MetaMorph software (Molecular Devices, Downingtown. PA).
Bone Histology: Forelimb and hind limb bones were removed from mice at the time of experimental termination. Tissues were fixed in 10% neutral buffered formalin for 48h, decalcified in 10% EDTA for 2 weeks, processed using an automated tissue processor (Excelsior, Thermoelectric), and embedded in paraffin. The sections were stained with hematoxylin and eosin with orange G and phloxine to visualize new bone.
RNA extraction and gene expression analysis
In vitro experiments: Total RNA was isolated using an Rneasy™ kit (Qiagen GmbH, Hilden Germany). In vivo experiments: The femur and tibiae from mice were dissected and cleaned from adhering tissues. The cartilage ends were cut off and the tumor cells in the marrow cavity were flushed out using cold PBS in a syringe with a sterile needle. After centrifugation, cells were resuspended in RNAlater™ (Qiagen) and total RNA was isolated with TRIzol 
Statistical analyses
Differences in osteolytic lesion areas between groups were determined by one-way ANOVA and two-way ANOVA. Kaplan-Meier survival curve data were analyzed by Logrank test. All results were expressed as mean ± SEM, and p<0.05 was considered significant (GraphPad Prism).
RESULTS AND DISCUSSION
The role of TGF-β in melanoma progression and metastasis is controversial. Using a specific Smad-dependent transcription assay as well as Smad/DNA interaction assays based upon our original characterization of hCOL7A1 as a Smad3/4 gene target (27) , we previously demonstrated that human melanoma cells secrete active TGF-β and exhibit both high constitutive, ligand-induced, Smad signaling (14) . Subsequently, others have shown that TGF-β that is produced by melanoma cells contributes to peri-tumoral stroma remodeling, providing a survival advantage to melanoma cells (28) . Contrasting with these results, it has also been proposed that the oncoproteins c-Ski and SnoN, known to interfere with Smad signaling (29) , are expressed at high levels in melanoma cells, and may be responsible for the lack of growth inhibitory activity of TGF-β in these cells (30, 31) . Recently, we demonstrated that overexpression of Smad7 in melanoma cells inhibits endogenous constitutive Smad signaling, reduces MMP secretion, and delays tumorigenicity both in vitro and in a model of sub-cutaneous tumor formation in nude mice (15) . These apparently contradictory results regarding the role of autocrine TGF-β signaling in melanoma cells led us to re-evaluate the activation status of Smad signaling obtained in a number of available melanoma cell lines.
Most transcriptional responses to TGF-β in the adult are mediated by Smad3/4 while it is generally accepted that Smad2 is critical during embryonic life (9) . We thus focused our attention on Smad3/4 status and activation. As shown in Fig. 1A , the various cell lines tested exhibited variable basal levels of P-Smad3, a marker of TGF-β receptor activation (Fig. 1A) .
In all cases, exogenously added TGF-β further induced a dramatic elevation of P-Smad3 levels, indicative of functional TGF-β receptor complexes (Fig. 1B) . Transient cell transfection experiments with the Smad3/4-specific reporter construct (CAGA) 9 -lux (23) indicated that most cell lines responded to exogenous TGF-β with a robust transcriptional response (Fig. 1C) , indicative of functional TGF-β/Smad signal transduction cascade all the way from the cell membrane to the nucleus. These results are in full agreement with our initial observations (14) , and consistent with the accepted concept of an autocrine and oncogenic role for TGF-β in late-stage carcinogenesis -reviewed in (32, 33) .
TGF-β expression is often increased in tumor cells and has been correlated with the advanced stage of melanoma progression (34) . We thus wanted to determine whether an auto-regulatory loop controlled TGF-β expression in melanoma cells. Firstly, using quantitative real-time-PCR, we determined that all melanoma cell lines available in the laboratory expressed the three TGF-β isoforms (not shown). TGF-β1 expression was predominant, with relative expression levels 10-to 20-fold higher than those for TGF-β3 (not shown). TGF-β2 was expressed at very low levels (100-to 1000-fold less than TGF-β1). These results are consistent with previously published observations (35) . Incubation of some of these cell lines, selected based on their robust Smad-specific transcriptional response to TGF-β (see Fig. 1C )
with exogenous TGF-β1 for 24h led to a consistently observed increase in the expression of TGF-β1, which was totally abrogated by the ALK5 inhibitor SB431542 (Fig. 2A) . Expression of TGF-β2 mRNA was also induced by TGF-β1 treatment (Fig. 2B) , however it only occurred in 50% of the cell lines tested (not shown). Again, incubation with the ALK5
inhibitor SB431542 led to a complete abrogation of TGF-β2 induction by exogenous TGF-β1.
Of note, no modulation of TGF-β3 expression was observed after either TGF-β1 or SB431542 treatment in any of the cell lines tested (not shown), suggesting its independence from Smad signaling.
To determine whether melanoma cells secrete active TGF-β that could induce stroma activation, melanoma cell culture supernatants were studied for their capacity to activate the Smad pathway in fibroblasts in culture. Incubation of WI-26 human lung fibroblasts with conditioned media from four distinct melanoma cell lines exhibiting constitutive Smad3/4 activation and TGF-β1 expression induced both rapid and sustained Smad3 phosphorylation in WI-26 cells (Fig. 2C) , and potent transactivation of the transfected (CAGA) 9 -lux construct (Fig. 2D) . Incubation with W849 un-conditioned medium did not induce any of these TGF-β-specific responses. Together, these results emphasize the fact that ligand-dependent constitutive activation of the Smad pathway in melanoma cells translates into production of active TGF-β that is highly capable of inducing both autocrine and paracrine (stromal) responses.
It is expected from our data on the expression of the three TGF-β isoforms (see above) that TGF-β1, and TGF-β3, represent the majority of constitutively produced isoforms capable of driving Smad signaling in melanoma cells, even in the presence of a TβRI inhibitor.
Furthermore, TGF-β1, and TGF-β2, is likely to be induced further in tissue environments rich in TGF-β, such as in late-stage cancer progression.
We previously demonstrated that TGF-β promotes bone metastases from solid tumors such as breast cancer (16, 17, 19) . Thus, given our recent data linking autocrine TGF-β signaling to melanoma aggressiveness (15), we decided to test the role of autocrine TGF-β signaling in melanoma metastases to bone by overexpressing the inhibitory Smad7 in a cell line with high endogenous Smad activity. For this purpose, we used 1205Lu cells as, (a), they exhibit high autonomous, ligand-induced, constitutive TGF-β/Smad signaling; (b), they exhibit a strong transcriptional response to exogenous TGF-β; (c) they are highly invasive in a Matrigel™ assay, and (d), they are highly tumorigenic in vivo (15) . Furthermore, we previously demonstrated that Smad7 overexpression in 1205Lu melanoma cells reduces MMP-2 and MMP-9 production, as well as their capacity to invade Matrigel™ and to establish subcutaneous tumors in nude mice (15) . Bone metastases appeared to be mostly osteolytic, but some osteoblastic lesions were also found (Supplementary data, Fig. 1 ). In addition, soft tissue metastases to various organsadrenal glands, lungs, liver and skin -appeared in all test mice (n=6) 5-10 weeks after tumor inoculation (not shown).
Next, 1205Lu melanoma cells were stably transfected with pcDNA-Smad7. In the first experiment, Smad7-overexpressing clones were compared with parental 1205Lu. All mice properties (42) . TGF-β blockade has been effective to reduce breast cancer metastases to bone and other sites in mouse models (41, (43) (44) (45) (46) (47) . In concordance, our results support the notion that blockade, or attenuation, of intracellular TGF-β signaling may be beneficial for the treatment of melanoma, another aggressive solid tumor able to generate bone metastases. 
Figure 4
Sub-confluent melanoma cell cultures (Mock-transfected and clones S7.a and S7.c) were pre-incubated for 6h in medium containing 1% serum before stimulation with TGF-β1. 
